These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 24930432)
1. Production of recombinant botulism antigens: a review of expression systems. Moreira GM; Cunha CE; Salvarani FM; Gonçalves LA; Pires PS; Conceição FR; Lobato FC Anaerobe; 2014 Aug; 28():130-6. PubMed ID: 24930432 [TBL] [Abstract][Full Text] [Related]
2. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D. Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078 [TBL] [Abstract][Full Text] [Related]
3. Enhancing toxin-based vaccines against botulism. Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477 [TBL] [Abstract][Full Text] [Related]
4. Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D. Cunha CE; Moreira GM; Salvarani FM; Neves MS; Lobato FC; Dellagostin OA; Conceição FR Vaccine; 2014 Jan; 32(2):214-6. PubMed ID: 24252701 [TBL] [Abstract][Full Text] [Related]
6. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522 [TBL] [Abstract][Full Text] [Related]
7. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D. Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080 [TBL] [Abstract][Full Text] [Related]
8. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341 [TBL] [Abstract][Full Text] [Related]
9. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain. Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503 [TBL] [Abstract][Full Text] [Related]
10. Humoral Response of Buffaloes to a Recombinant Vaccine against Botulism Serotypes C and D. Otaka DY; Barbosa JD; Moreira C; Ferreira MRA; Cunha CEP; Brito ARS; Donassolo RA; Moreira ÂN; Conceição FR; Salvarani FM Toxins (Basel); 2017 Sep; 9(10):. PubMed ID: 28937601 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829 [TBL] [Abstract][Full Text] [Related]
12. Recombinant Botulinum Toxoids: A Practical Guide for Production. Moreira GMSG; Moreira C; da Cunha CEP; Mendonça M; Conceição FR Methods Mol Biol; 2016; 1404():621-632. PubMed ID: 27076326 [TBL] [Abstract][Full Text] [Related]
13. Botulism and vaccines for its prevention. Smith LA Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283 [TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619 [TBL] [Abstract][Full Text] [Related]
16. Development of vaccines for prevention of botulism. Byrne MP; Smith LA Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225 [TBL] [Abstract][Full Text] [Related]
17. High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E. Valipour E; Moosavi ML; Amani J; Nazarian S World J Microbiol Biotechnol; 2014 Jun; 30(6):1861-7. PubMed ID: 24469548 [TBL] [Abstract][Full Text] [Related]
18. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Lee JC; Hwang HJ; Sakaguchi Y; Yamamoto Y; Arimitsu H; Tsuji T; Watanabe T; Ohyama T; Tsuchiya T; Oguma K Microbiol Immunol; 2007; 51(4):445-55. PubMed ID: 17446685 [TBL] [Abstract][Full Text] [Related]
19. Association of toxin-producing Clostridium botulinum with the macroalga Cladophora in the Great Lakes. Chun CL; Ochsner U; Byappanahalli MN; Whitman RL; Tepp WH; Lin G; Johnson EA; Peller J; Sadowsky MJ Environ Sci Technol; 2013 Mar; 47(6):2587-94. PubMed ID: 23421373 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle. Moreira C; Ferreira MRA; da Cunha CEP; Donassolo RA; Finger PF; Moreira GMSG; Otaka DY; de Sousa LA; Barbosa JD; Moreira ÂN; Salvarani FM; Conceição FR Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30241350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]